Drug Trial Radar · NCT01519778
A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study
Last checked: Nov 20, 2026Latest source record: Aug 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Feb 15, 2012
Primary completion
Aug 27, 2012
Study completion Aug 27, 2012
Sponsor
- Lead sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Jan 27, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.
Conditions
- Major Cutaneous Abscess
- Cellulitis
- Erysipelas
Interventions
TR701 FADrug
1 tablet 200 mg once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: 24-31 days
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Trius Investigator Site #118
Anaheim, California
Trius Investigator Site #129
Buena Park, California
Trius Investigator Site 103
Chula Vista, California
Trius Investigator Site 105
La Mesa, California
Trius Investigator Site #106
Long Beach, California
Trius Investigator Site 104
Oceanside, California
Trius Investigator Site 101
Columbus, Georgia
Trius Investigator Site 102
Savannah, Georgia
Trius Investigator Site 128
Las Vegas, Nevada
Trius Investigator Site 115
Somers Point, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.